Alaunos Therapeutics (TCRT) Net Cash Flow (2016 - 2025)
Historic Net Cash Flow for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$844000.0.
- Alaunos Therapeutics' Net Cash Flow fell 806.66% to -$844000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year increase of 7164.99%. This contributed to the annual value of -$5.0 million for FY2024, which is 8940.85% up from last year.
- Latest data reveals that Alaunos Therapeutics reported Net Cash Flow of -$844000.0 as of Q3 2025, which was down 806.66% from -$701000.0 recorded in Q2 2025.
- Over the past 5 years, Alaunos Therapeutics' Net Cash Flow peaked at $15.0 million during Q3 2021, and registered a low of -$23.3 million during Q2 2021.
- In the last 5 years, Alaunos Therapeutics' Net Cash Flow had a median value of -$5.9 million in 2023 and averaged -$6.1 million.
- Its Net Cash Flow has fluctuated over the past 5 years, first surged by 18298.61% in 2021, then plummeted by 57018.39% in 2023.
- Quarter analysis of 5 years shows Alaunos Therapeutics' Net Cash Flow stood at -$15.7 million in 2021, then surged by 107.98% to $1.3 million in 2022, then plummeted by 570.18% to -$5.9 million in 2023, then soared by 89.94% to -$592000.0 in 2024, then crashed by 42.57% to -$844000.0 in 2025.
- Its Net Cash Flow stands at -$844000.0 for Q3 2025, versus -$701000.0 for Q2 2025 and -$772000.0 for Q1 2025.